Top

Published in:

01-08-2002 | Commentary

Cyclins in breast cancer: too much of a good thing

Author: Greg H Enders

Published in: Breast Cancer Research | Issue 4/2002

Abstract

Cyclin E, a key mediator of entry into the cell division cycle, is expressed abundantly in many breast cancers. However, amplification of the cognate gene is observed rarely, leaving the responsible mechanism(s) and its importance in tumorigenesis in doubt. In a recent report, Steve Reed's lab demonstrates that hCdc4/Fbw7 targets cyclin E for ubiquitin-mediated proteolysis and is mutant in a breast cancer cell line with high cyclin E levels. Independent work demonstrates that a Drosophila hCdc4 homologue constrains cyclin E expression in vivo. These results suggest that lesions in protein degradation pathways may contribute to cyclin E deregulation in breast cancer.

Sherr CJ: Cancer Cell Cycles. Science. 1996, 274: 1672-1677. 10.1126/science.274.5293.1672.CrossRefPubMed

Keyomarsi K, Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA. 1993, 90: 1112-1116.CrossRefPubMedPubMedCentral

Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001, 413: 316-322. 10.1038/35095076.CrossRefPubMed

Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C: Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996, 69: 247-253. 10.1002/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.3.CO;2-Q.CrossRefPubMed

Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed

Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Hasla SZ, Bronson RT, Elledge S, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995, 82: 621-630.CrossRefPubMed

Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C: Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995, 9: 2364-2372.CrossRefPubMed

Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001, 411: 1017-1021. 10.1038/35082500.CrossRefPubMed

Spruck CH, Won KA, Reed SI: Deregulated cyclin E induces chromosome instability. Nature. 1999, 401: 297-300. 10.1038/45836.CrossRefPubMed

10.

Bortne DM, Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol. 1997, 17: 453-459.CrossRef

11.

Dutta A, Chandra R, Leiter LM, Lester S: Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA. 1995, 92: 5386-5390.CrossRefPubMedPubMedCentral

12.

Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997, 3: 222-225.CrossRefPubMed

13.

Won KA, Reed SI: Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 1996, 15: 4182-4193.PubMedPubMedCentral

14.

Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996, 10: 1979-1990.CrossRefPubMed

15.

Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ: SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell. 1996, 86: 263-274.CrossRefPubMed

16.

DeSalle LM, Pagano M: Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett. 2001, 490: 179-189. 10.1016/S0014-5793(01)02121-4.CrossRefPubMed

17.

Tyers M, Jorgensen P: Proteolysis and the cell cycle: with this RING I do thee destroy. Curr Opin Genet Dev. 2000, 10: 54-64. 10.1016/S0959-437X(99)00049-0.CrossRefPubMed

18.

Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, Mendenhall MD, Sicheri F, Pawson T, Tyers M: Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature. 2001, 414: 514-521. 10.1016/S0014-5793(97)01059-4.CrossRefPubMed

19.

Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001, 294: 173-177. 10.1126/science.1065203.CrossRefPubMed

20.

Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW: A family of mammalian F-box proteins. Curr Biol. 1999, 9: 1180-1182. 10.1016/S0960-9822(00)80021-4.CrossRefPubMed

21.

Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M: Identification of a family of human F-box proteins. Curr Biol. 1999, 9: 1177-1179. 10.1016/S0960-9822(00)80020-2.CrossRefPubMed

22.

Moberg KH, Bell DW, Wahrer DC, Haber DA, Harihara IK: Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001, 413: 311-316. 10.1016/S0370-2693(97)01128-3.CrossRefPubMed

23.

Schutte M, Hruba RH, Geradts J, Maynard R, Hilgers W, Rabindra SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Bayli SB, Ker SE, Herman JG: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997, 57: 3126-3130.PubMed

24.

Hu B, Mitra J, van den Heuvel S, Enders GH: S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant negative mutant in human cells. Mol Cell Biol. 2001, 21: 2755-2766. 10.1128/MCB.21.8.2755-2766.2001.CrossRefPubMedPubMedCentral

25.

Garrett MD, Fattaey A: CDK inhibition and cancer therapy. Curr Opin Genet Dev. 1999, 9: 104-111. 10.1016/S0959-437X(99)80015-X.CrossRefPubMed

Title: Cyclins in breast cancer: too much of a good thing
Author: Greg H Enders
Publication date: 01-08-2002
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 4/2002
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr439

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2002

Wnt signalling in mammary carcinogenesis

93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, USA, 6-10 April 2002

Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo

Finding the needle in the haystack: why high-throughput screening is good for your health

A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women

Novel mutations in the BRCA1 and BRCA2genes in Iranian women with early-onset breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer